share_log

Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss

Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss

bausch health公司(纽交所:BHC)的股东有了一个强劲的一周,但仍无法缓解为期三年的亏损之痛。
Simply Wall St ·  06/22 09:01

As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Bausch Health Companies Inc. (NYSE:BHC) investors who have held the stock for three years as it declined a whopping 77%. That'd be enough to cause even the strongest minds some disquiet. Shareholders have had an even rougher run lately, with the share price down 29% in the last 90 days.

作为投资者,犯错误是不可避免的,但是你想要像瘟疫一样避免真正的大损失。所以让我们考虑一下,巴沙健康公司(NYSE:BHC)的股东们,他们持有该股票三年以来股价暴跌了77%,即使是最强大的头脑也会感到烦扰。股东们近期的情况更加严峻,股价在过去90天中下跌了29%。

The recent uptick of 7.6% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近的7.6%上涨可能预示着未来可能会有好的迹象,因此让我们来看看历史基本面。

Given that Bausch Health Companies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鉴于巴沙健康公司在过去十二个月中没有盈利,我们将专注于营收增长以快速了解其业务发展情况。一般来说,没有盈利的公司每年都有望实现营收增长,而且增长速度很快。有些公司愿意推迟盈利以实现更快的营收增长,但在这种情况下,人们希望有良好的营收增长来弥补缺乏收益的情况。在三年内,巴沙健康公司的营收每年增长1.7%。考虑到它在追求增长的同时在亏损,我们对此并不感到印象深刻。但是股价每年下跌21%似乎有点严峻!虽然我们肯定对这只股票持谨慎态度,但在这种表现之后,这可能是一种过度反应。在考虑购买之前,请查看公司正在积累的损失情况。

Over three years, Bausch Health Companies grew revenue at 1.7% per year. Given it's losing money in pursuit of growth, we are not really impressed with that. But the share price crash at 21% per year does seem a bit harsh! While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Before considering a purchase, take a look at the losses the company is racking up.

虽然整个市场去年增长了26%左右,但巴沙健康公司的股东们却亏损了5.4%。即使好股票的股票价格有时也会下跌,但是在对业务基本指标产生兴趣之前,我们希望看到实质性的改善。不幸的是,长期股东的损失更大,因为在过去五年中他们损失了12%。在采取认为股票价格将稳定的观点之前,我们希望获得明确的信息表明公司将会增长。我认为,从长期来看,观察股票价格作为业务绩效的代理是非常有趣的。但是为了真正获得洞察力,我们还需要考虑其他信息。为此,您应该了解我们发现巴沙健康公司的1个警告标志。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

你可以在下面的图片中看到收入和营业收入随时间的变化情况(单击图表可查看精确值)。

earnings-and-revenue-growth
NYSE:BHC Earnings and Revenue Growth June 22nd 2024
NYSE:BHC 财务数据及营收增长 2024年6月22日

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

资产负债表强度至关重要。查看我们关于其财务状况如何随时间变化的免费报告可能很值得一看。

A Different Perspective

不同的观点

While the broader market gained around 26% in the last year, Bausch Health Companies shareholders lost 5.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 12% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Bausch Health Companies .

尽管整个市场去年增长了约26%,但巴沙健康公司的股东们却亏损了5.4%。即使好股票的股票价格有时也会下跌,但在对业务基本指标产生兴趣之前,我们希望看到实质性的改善。不幸的是,长期股东的损失更大,因为在过去五年中,他们损失12%。在采取认为股票价格将稳定的观点之前,我们希望获得明确的信息表明公司将会增长。我认为,从长期来看,观察股票价格作为业务绩效的代理是非常有趣的。但是为了真正获得洞察力,我们还需要考虑其他信息。为此,您应该了解我们发现巴沙健康公司的1个警告标志。

But note: Bausch Health Companies may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

请注意:巴沙健康公司可能不是最好的股票选择。因此,请查看此列表,其中包含过去盈利增长(以及进一步的增长预测)的有趣公司。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发